Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Keratosis, Actinic 1Carcinoma, Basal Cell 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT00472043 2024-08-06

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Galderma R&D

Phase 3 Completed
66 enrolled 15 charts
Dermatologic

Carcinoma, Basal Cell

NCT01966120 2023-07-28

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

Biofrontera Bioscience GmbH

Phase 3 Completed
87 enrolled 21 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡